Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities

Genome Biology

Volumn 17, Issue 1, 2016, Pages

  Nazeen, Sumaiya ^a   Palmer, Nathan P ^b   Berger, Bonnie ^a,c   Kohane, Isaac S ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Autism spectrum disorder; Co morbidities of ASD; Gene expression; Innate immunity pathways; Three tiered meta analysis

Indexed keywords

CHEMOKINE; TOLL LIKE RECEPTOR; TRANSCRIPTOME;

ACCURACY; ARTICLE; AUTISM; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC DATABASE; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTEGRATIVE MEDICINE; MENTAL DISEASE; SEIZURE; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TRANSCRIPTOMICS; COMPLICATION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; META ANALYSIS;

AUTISM SPECTRUM DISORDER; COMORBIDITY; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84995814270     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-016-1084-z     Document Type: Article

References (114)

1. Loscalzo J, Kohane I, Barabási AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007; 3(1):124.
2. Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011; 12(1):56-68.
3. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3(96):77.
4. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013; 11(1):126.
5. Insel TR. Mental disorders in childhood: shifting the focus from behavioral symptoms to neurodevelopmental trajectories. JAMA. 2014; 311(17):1727-8.
6. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012; 74(2):285-99.
7. Neale BM, Kou Y, Liu L, Ma'Ayan A, Samocha KE, Sabo A, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012; 485(7397):242-5.
8. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012; 485(7397):237-41.
9. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012; 485(7397):246-50.
10. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012; 148(6):1223-41.
11. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B, et al. Using whole-exome sequencing to identify inherited causes of autism. Neuron. 2013; 77(2):259-73.
12. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 2014; 94(5):677-94.
13. Lin GN, Corominas R, Lemmens I, Yang X, Tavernier J, Hill DE, et al. Spatiotemporal 16p11. 2 protein network implicates cortical late mid-fetal brain development and KCTD13-Cul3-RhoA pathway in psychiatric diseases. Neuron. 2015; 85(4):742-54.
14. Smoller J, Craddock N, Kendler K, Lee P, Neale B, Nurnberger J, et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875):1371-9.
15. Levy D, Ronemus M, Yamrom B, Lee Y-H, Leotta A, Kendall J, et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron. 2011; 70(5):886-97.
16. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008; 82(2):477-88.
17. Bijlsma E, Gijsbers A, Schuurs-Hoeijmakers J, Van Haeringen A, Van De Putte DF, Anderlid BM, et al. Extending the phenotype of recurrent rearrangements of 16p11. 2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet. 2009; 52(2):77-87.
18. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, et al. Microduplications of 16p11. 2 are associated with schizophrenia. Nat Genet. 2009; 41(11):1223-7.
19. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11. 2 and autism. N Engl J Med. 2008; 358(7):667-75.
20. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010; 466(7304):368-72.
21. Béna F, Bruno DL, Eriksson M, van Ravenswaaij-Arts C, Stark Z, Dijkhuizen T, et al. Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature. Am J Med Genet B Neuropsychiatr Genet. 2013; 162(4):388-403.
22. Moreno-De-Luca D, Sanders S, Willsey A, Mulle J, Lowe J, Geschwind D, et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatr. 2013; 18(10):1090-5.
23. Carter M, Scherer S. Autism spectrum disorder in the genetics clinic: a review. Clin Genet. 2013; 83(5):399-407.
24. Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, et al. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS ONE. 2012; 7(4):33224.
25. Doshi-Velez F, Ge Y, Kohane IS. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics. 2014; 133(1):54-63.
26. Mouridsen SE, Rich B, Isager T. Epilepsy in disintegrative psychosis and infantile autism: a long-term validation study. Dev Med Child Neurol. 1999; 41(02):110-14.
27. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002; 1(6):352-8.
28. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999; 135(5):559-63.
29. Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002; 14(5):583-7.
30. Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, & possible biopsychosocial aetiologies. Sleep Med Rev. 2009; 13(6):403-11.
31. Wu JY, Kuban KC, Allred E, Shapiro F, Darras BT. Association of Duchenne muscular dystrophy with autism spectrum disorder. J Child Neurol. 2005; 20(10):790-5.
32. Hendriksen J, Vles J. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol. 2008; 23(5):477-81.
33. Hinton VJ, Cyrulnik SE, Fee RJ, Batchelder A, Kiefel JM, Goldstein EM, et al. Association of autistic spectrum disorders with dystrophinopathies. Pediatr Neurol. 2009; 41(5):339-46.
34. Morgan CN, Roy M, Chance P. Psychiatric comorbidity and medication use in autism: a community survey. Psychiatrist. 2003; 27(10):378-81.
35. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?. Pediatr Res. 2011; 69:26-33.
36. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009; 10(1):43-55.
37. Robinson WH, Fontoura P, Lee BJ, de Vegvar HEN, Tom J, Pedotti R, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol. 2003; 21(9):1033-9.
38. Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013; 5(188):75.
39. Fisher RA. Statistical methods for research workers, 5th edn. Biological monographs and manuals. Edinburgh: Oliver and Boyd Ltd; 1934.
40. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009; 22(2):240-73.
41. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011; 25(1):40-5.
42. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun. 2010; 24(1):64-71.
43. Verkhratsky A, Rodríguez JJ, Parpura V. Neuroglia in ageing and disease. Cell Tissue Res. 2014; 357(2):493-503.
44. Malkova NV, Collin ZY, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun. 2012; 26(4):607-16.
45. Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun. 2009; 23(1):124-33.
46. Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, et al. Unexpected role of interferon- γ in regulating neuronal connectivity and social behaviour. Nature. 2016. doi: 10.1038/nature18626.
47. Suh HS, Kim MO, Lee SC. Inhibition of granulocyte-macrophage colony-stimulating factor signaling and microglial proliferation by anti-CD45RO: role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt. J Immunol. 2005; 174(5):2712-19.
48. Fatemi SH. Multiple pathways in prevention of immune-mediated brain disorders: implications for the prevention of autism. J Neuroimmunol. 2009; 217(1-2):8.
49. Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol. 2009; 217(1):20-7.
50. Polan MB, Pastore MT, Steingass K, Hashimoto S, Thrush DL, Pyatt R, et al. Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a GABAA receptor subunit gene cluster. Eur J Hum Genet. 2014; 22(1):105-9.
51. Pramparo T, Pierce K, Lombardo MV, Barnes CC, Marinero S, Ahrens-Barbeau C, et al. Prediction of autism by translation and immune/inflammation coexpressed genes in toddlers from pediatric community practices. JAMA Psychiatr. 2015; 72(4):386-94.
52. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3(1):1-25.
53. Murie C, Woody O, Lee AY, Nadon R. Comparison of small n statistical tests of differential expression applied to microarrays. BMC Bioinform. 2009; 10(1):1.
54. Tesse R, Pandey R, Kabesch M. Genetic variations in Toll-like receptor pathway genes influence asthma and atopy. Allergy. 2011; 66(3):307-16.
55. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov. 2002; 1(10):797-807.
56. Lin J, Caye-Thomasen P, Tono T, Zhang QA, Nakamura Y, Feng L, et al. Mucin production and mucous cell metaplasia in otitis media. Int J Otolaryngol. 2012; 2012:745325. doi: 10.1155/2012/745325.
57. Kimura H, Yoshizumi M, Ishii H, Oishi K, Ryo A. Cytokine production and signaling pathways in respiratory virus infection. Front Microbiol. 2013; 4(276):2.
58. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov. 2010; 9(4):293-307.
59. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-42.
60. Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P, et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol. 2004; 34(7):1992-2000.
61. Ramos PS, Sajuthi S, Langefeld CD, Walker SJ. Immune function genes CD99L2, JARID2 and TPO show association with autism spectrum disorder. Mol Autism. 2012; 3(1):1-5.
62. Saxena V, Ramdas S, Ochoa CR, Wallace D, Bhide P, Kohane I. Structural, genetic, and functional signatures of disordered neuro-immunological development in autism spectrum disorder. PLoS ONE. 2012; 7(12):48835.
63. Garbett KA, Hsiao EY, Kálmán S, Patterson PH, Mirnics K. Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl Psychiatr. 2012; 2(4):98.
64. Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y. Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clin Immunol. 2009; 130(3):235-43.
65. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009; 207(1):111-16.
66. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007; 27(40):10695-702.
67. Kong S, Shimizu-Motohashi Y, Campbell M, Lee I, Collins C, Brewster S, et al. Peripheral blood gene expression signature differentiates children with autism from unaffected siblings. Neurogenetics. 2013; 14(2):143-52.
68. Voineagu I, Eapen V. Converging pathways in autism spectrum disorders: interplay between synaptic dysfunction and immune responses. Front Hum Neurosci. 2013; 7:738.
69. Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci. 2015; 16(8):469-86.
70. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatr. 2013; 70(1):49-58.
71. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun. 2014; 5:5748.
72. Kim H, Cho M, Shim W, Kim J, Jeon E, Kim D, et al. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. Mol Psychiatr. 2016. doi: 10.1038/mp.2016.103.
73. Campbell MG, Kohane IS, Kong SW. Pathway-based outlier method reveals heterogeneous genomic structure of autism in blood transcriptome. BMC Med Genet. 2013; 6(1):34.
74. Jyonouchi H, Geng L, Davidow AL. Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype?. J Neuroinflamm. 2014; 11(1):187.
75. West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, et al. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS ONE. 2014; 9(11):112445.
76. Atladóttir HÓ, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009; 124(2):687-94.
77. Brown AS, Sourander A, Hinkka-Yli-Salomäki S, McKeague I, Sundvall J, Surcel H. Elevated maternal C-reactive protein and autism in a national birth cohort. Mol Psychiatr. 2014; 19(2):259-64.
78. Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010; 40(12):1423-30.
79. Atladóttir HÓ, Henriksen TB, Schendel DE, Parner ET. Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatrics. 2012; 130(6):1447-54.
80. Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res. 2010; 9(6):2996-3004.
81. Kang DW, Park JG, Ilhan ZE, Wallstrom G, LaBaer J, Adams JB, et al. Reduced incidence of Prevotellaand other fermenters in intestinal microflora of autistic children. PLoS ONE. 2013; 8(7):68322.
82. Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA, et al. Increased abundance of Sutterella spp, and Ruminococcus torques in feces of children with autism spectrum disorder. Mol Autism. 2013; 4(1):42.
83. De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS ONE. 2013; 8(10):e76993.
84. Mayer EA, Padua D, Tillisch K. Altered brain-gut axis in autism: comorbidity or causative mechanisms?. Bioessays. 2014; 36(10):933-9.
85. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7.
86. Sellke T, Bayarri M, Berger JO. Calibration of ρ values for testing precise null hypotheses. Am Stat. 2001; 55(1):62-71.
87. Johnson VE. Bayes factors based on test statistics. J R Stat Soc Ser B Stat Methodol. 2005; 67(5):689-701.
88. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med. 1999; 130(12):1005-13.
89. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30(1):207-10.
90. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013; 41(D1):991-5.
91. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000; 28(1):27-30.
92. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012; 40(D1):D109-D114.
93. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014; 42(D1):472-7.
94. Monaco MK, Stein J, Naithani S, Wei S, Dharmawardhana P, Kumari S, et al. Gramene 2013: comparative plant genomics resources. Nucleic Acids Research. 2014; 42(D1):1193-9.
95. Nishimura D. BioCarta. Biotech Softw Internet Rep Comput Softw J Scient. 2001; 2(3):117-20.
96. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the pathway interaction database. Nucleic Acids Res. 2009; 37(suppl 1):674-9.
97. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102(43):15545-50.
98. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/, Accessed 29 Sept 2016.
99. Molecular Signatures Database. http://www.broadinstitute.org/gsea/msigdb/collections.jsp. Accessed 29 Sep 2016.
100. Becker KG. Autism, asthma, inflammation, and the hygiene hypothesis. Med Hypotheses. 2007; 69(4):731-40.
101. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol. 2012; 71(4):444-57.
102. Curatolo P, Porfirio MC, Manzi B, Seri S. Autism in tuberous sclerosis. Eur J Paediatr Neurol. 2004; 8(6):327-32.
103. Loirat C, Bellanné-Chantelot C, Husson I, Deschênes G, Guigonis V, Chabane N. Autism in three patients with cystic or hyperechogenic kidneys and chromosome 17q12 deletion. Nephrol Dial Transpl. 2010; 25(10):3430-3.
104. Surén P, Bakken IJ, Aase H, Chin R, Gunnes N, Lie KK, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics. 2012; 130(1):152-8.
105. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 2003; 23(1):58-77.
106. Bilder D, Botts EL, Smith KR, Pimentel R, Farley M, Viskochil J, et al. Excess mortality and causes of death in autism spectrum disorders: a follow up of the 1980s Utah/UCLA autism epidemiologic study. J Autism Dev Disord. 2013; 43(5):1196-204.
107. Konstantareas MM, Homatidis S. Brief report: ear infections in autistic and normal children. J Autism Dev Disord. 1987; 17(4):585-94.
108. Rosenhall U, Nordin V, Sandström M, Ahlsen G, Gillberg C. Autism and hearing loss. J Autism Dev Disord. 1999; 29(5):349-57.
109. Porges SW, Macellaio M, Stanfill SD, McCue K, Lewis GF, Harden ER, et al. Respiratory sinus arrhythmia and auditory processing in autism: modifiable deficits of an integrated social engagement system?. Int J Psychophysiol. 2013; 88(3):261-70.
110. Walker SJ, Fortunato J, Gonzalez LG, Krigsman A. Identification of unique gene expression profile in children with regressive autism spectrum disorder (ASD) and ileocolitis. PLoS ONE. 2013; 8(3):58058.
111. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J Autism Dev Disord. 2001; 31(6):569-76.
112. Tabares-Seisdedos R, Rubenstein J. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatr. 2009; 14(6):563-89.
113. Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen O, et al. Copy number variations of chromosome 16p13. 1 region associated with schizophrenia. Mol Psychiatr. 2011; 16(1):17-25.
114. Murdoch JD, State MW. Recent developments in the genetics of autism spectrum disorders. Curr Opin Genet Dev. 2013; 23(3):310-5.